Media headlines about Chiasma (NASDAQ:CHMA) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chiasma earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.6965436960059 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Chiasma (CHMA) traded up 4.55% during trading on Friday, hitting $2.30. The company had a trading volume of 126,739 shares. Chiasma has a one year low of $1.25 and a one year high of $3.71. The stock’s market capitalization is $56.03 million. The stock has a 50-day moving average of $1.65 and a 200-day moving average of $1.58.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/chiasma-chma-given-daily-media-sentiment-rating-of-0-20.html.

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.